{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:38:56Z","timestamp":1793050736985,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006955","name":"National Institutes of Health Office of Extramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"The Mark Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.celrep.2026.117717","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:04:34Z","timestamp":1784534674000},"page":"117717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer"],"prefix":"10.1016","volume":"45","author":[{"given":"Marc","family":"Creixell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yi","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Loui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Boixo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Creixell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest M.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-1840","authenticated-orcid":false,"given":"Aaron S.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117717_bib1","series-title":"Cancer Facts & Figures 2022","year":"2022"},{"key":"10.1016\/j.celrep.2026.117717_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.117717_bib3","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1038\/ncomms13898","article-title":"Reprogramming the immunological microenvironment through radiation and targeting Axl","volume":"7","author":"Aguilera","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117717_bib4","first-page":"27","article-title":"AXL receptor tyrosine kinase as a therapeutic target in NSCLC","volume":"6","author":"Okimoto","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.celrep.2026.117717_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004155","article-title":"The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells","volume":"6","author":"Meyer","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2026.117717_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2020.01.015","article-title":"AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells","volume":"15","author":"Lotsberg","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.celrep.2026.117717_bib7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117717_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-017-0579-4","article-title":"Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies","volume":"19","author":"Schoumacher","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.celrep.2026.117717_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","article-title":"AXL mediates resistance to PI3K\u03b1 inhibition by activating the EGFR\/PKC\/mTOR Axis in Head and neck and esophageal squamous cell carcinomas","volume":"27","author":"Elkabets","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.celrep.2018.04.019","article-title":"The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression","volume":"23","author":"Goyette","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117717_bib11","doi-asserted-by":"crossref","first-page":"89761","DOI":"10.18632\/oncotarget.21125","article-title":"Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117717_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1078-0432.CCR-13-1354","article-title":"AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer","volume":"20","author":"Dunne","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2326-6066.CIR-18-0903","article-title":"AXL targeting overcomes human lung cancer cell resistance to NK- And CTL-mediated cytotoxicity","volume":"7","author":"Terry","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2026.117717_bib14","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-17-0392","article-title":"AXL-driven EMT state as a targetable conduit in cancer","volume":"77","author":"Antony","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117717_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib17","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","article-title":"Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis","volume":"75","author":"Kirane","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4161\/15384047.2014.956634","article-title":"Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells","volume":"15","author":"P\u00e9nzes","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.celrep.2026.117717_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17415-x","article-title":"AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network","volume":"11","author":"Abu-Thuraia","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117717_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/1541-7786.MCR-21-0275","article-title":"Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration","volume":"20","author":"Majumder","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117717_bib22","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","article-title":"AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.celrep.2026.117717_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11912-023-01392-7","article-title":"AXL Inhibitors: Status of Clinical Development","volume":"25","author":"Bhalla","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.celrep.2026.117717_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2471","article-title":"1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)","volume":"34","author":"Felip","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.celrep.2026.117717_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.01.275","article-title":"OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC","volume":"16","author":"Krebs","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.celrep.2026.117717_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf138","article-title":"Phase 1b\/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma","volume":"30","author":"Beckermann","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.celrep.2026.117717_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.650","article-title":"A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours","volume":"31","author":"Adjei","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.celrep.2026.117717_bib28","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jtho.2024.05.155","article-title":"PPD01.07 Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.celrep.2026.117717_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2023.41.6_suppl.666","article-title":"A phase 1b\/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)","volume":"41","author":"Shah","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.117717_bib30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.sbi.2009.10.001","article-title":"SH2 domains: modulators of nonreceptor tyrosine kinase activity","volume":"19","author":"Filippakopoulos","year":"2009","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.celrep.2026.117717_bib31","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1158\/1078-0432.CCR-19-3142","article-title":"AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer","volume":"26","author":"McDaniel","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cels.2015.06.002","article-title":"The AXL Receptor Is a Sensor of Ligand Spatial Heterogeneity","volume":"1","author":"Meyer","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.celrep.2026.117717_bib33","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/1541-7786.MCR-17-0012","article-title":"Apoptotic Bodies Elicit Gas6-Mediated Migration of AXL-Expressing Tumor Cells","volume":"15","author":"Zweemer","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/3212829","article-title":"The second-order analysis of stationary point processes","volume":"13","author":"Ripley","year":"1976","journal-title":"J. Appl. Probab."},{"key":"10.1016\/j.celrep.2026.117717_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3847\/1538-4357\/ac7c74","article-title":"The Astropy Project: Sustaining and Growing a Community-oriented Open-source Project and the Latest Major Release (v5.0) of the Core Package","volume":"935","author":"Collaboration","year":"2022","journal-title":"Astrophys. J."},{"key":"10.1016\/j.celrep.2026.117717_bib36","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1073\/pnas.1521288113","article-title":"Early signaling dynamics of EGFR","volume":"113","author":"Reddy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117717_bib37","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-16-0123","article-title":"JNK pathway activation modulates acquired resistance to EGFR\/HER2-targeted therapies","volume":"76","author":"Manole","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib38","article-title":"Dual data and motif clustering improves the modeling and interpretation of phosphoproteomic data","volume":"2","author":"Creixell","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.celrep.2026.117717_bib39","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.18632\/oncotarget.2422","article-title":"Axl as a mediator of cellular growth and survival","volume":"5","author":"Axelrod","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117717_bib40","doi-asserted-by":"crossref","first-page":"D433","DOI":"10.1093\/nar\/gky1159","article-title":"15 years of PhosphoSitePlus \u00ae : Integrating post-translationally modified sites, disease variants and isoforms","volume":"47","author":"Hornbeck","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117717_bib41","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-023-02468-8","article-title":"The Cyclin-dependent kinase 1: more than a cell cycle regulator","volume":"129","author":"Massacci","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117717_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1091\/mbc.3.1.13","article-title":"Role of Phosphorylation in p34cdc2 Activation: Identification of an Activating Kinase","volume":"3","author":"Solomon","year":"1992","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib43","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1074\/mcp.M110.001586","article-title":"SH2 Domains Recognize Contextual Peptide Sequence Information to Determine Selectivity\u2217 \u25a1 S","volume":"9","author":"Liu","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.celrep.2026.117717_bib44","first-page":"3","article-title":"Molecular functions of SIRP\u03b1 and its role in cancer","volume":"9","author":"Takahashi","year":"2018","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.celrep.2026.117717_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","article-title":"Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib46","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/1535-7163.MCT-21-0293","article-title":"AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2026.117717_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.332","article-title":"A chemical and phosphoproteomic characterization of dasatinib action in lung cancer","volume":"6","author":"Li","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117717_bib49","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.18632\/oncotarget.2397","article-title":"Overcoming EMT-associated resistance to anti-cancer drugs via Src\/FAK pathway inhibition","volume":"5","author":"Wilson","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117717_bib50","doi-asserted-by":"crossref","first-page":"e35190","DOI":"10.7554\/eLife.35190","article-title":"Fine-tuning of substrate preferences of the Src-family kinase Lck revealed through a high-throughput specificity screen","volume":"7","author":"Shah","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2026.117717_bib51","article-title":"High-throughput profiling of sequence recognition by tyrosine kinases and SH2 domains using bacterial peptide display","volume":"12","author":"Li","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2026.117717_bib52","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41586-024-07407-y","article-title":"The intrinsic substrate specificity of the human tyrosine kinome","volume":"629","author":"Yaron-Barir","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117717_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau2875","article-title":"Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer","volume":"12","author":"Schwill","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2026.117717_bib54","series-title":"The TAM Family: Phosphatidylserine-Sensing Receptor Tyrosine Kinases Gone Awry in Cancer","author":"Graham","year":"2014"},{"key":"10.1016\/j.celrep.2026.117717_bib55","doi-asserted-by":"crossref","first-page":"34954","DOI":"10.1074\/jbc.M109.072660","article-title":"Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: An analysis of ACK1 effects on Axl signaling","volume":"284","author":"Pao-Chun","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2026.117717_bib56","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/0008-5472.CAN-07-6205","article-title":"Negative Regulation of YAP by LATS1 Underscores Evolutionary Conservation of the Drosophila Hippo Pathway","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib57","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","article-title":"The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells","volume":"147","author":"Cordenonsi","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib58","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/1541-7786.MCR-18-0158","article-title":"YAP tyrosine phosphorylation and nuclear localization in cholangiocarcinoma cells are regulated by LCK and independent of LATS activity","volume":"16","author":"Sugihara","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the Roots of Cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ Signaling and Resistance to Cancer Therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.celrep.2026.117717_bib61","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.neo.2017.10.003","article-title":"YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC","volume":"19","author":"Ghiso","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.celrep.2026.117717_bib62","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-022-32674-6","article-title":"CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis","volume":"13","author":"Guo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117717_bib63","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-018-0658-1","article-title":"The SWI\/SNF complex is a mechanoregulated inhibitor of YAP and TAZ","volume":"563","author":"Chang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117717_bib64","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/cam4.3734","article-title":"Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma","volume":"10","author":"Park","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.celrep.2026.117717_bib65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib66","article-title":"The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors","volume":"9","author":"Saab","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib67","doi-asserted-by":"crossref","first-page":"114576","DOI":"10.18632\/oncotarget.23051","article-title":"YAP regulates PD-L1 expression in human NSCLC cells","volume":"8","author":"Miao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117717_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47423-0","article-title":"A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 2 3","author":"Haderk","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117717_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-023-02606-3","article-title":"Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer","volume":"42","author":"Yu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117717_bib70","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.celrep.2015.09.014","article-title":"Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins","volume":"13","author":"Wang","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117717_bib71","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Wilson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117717_bib72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005125","article-title":"Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer","volume":"7","author":"Tao","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2026.117717_bib74","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ccr.2011.07.011","article-title":"Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers","volume":"20","author":"Wilson","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117717_bib75","doi-asserted-by":"crossref","first-page":"51922","DOI":"10.18632\/oncotarget.10458","article-title":"YAP promotes erlotinib resistance in human non-small cell lung cancer cells","volume":"7","author":"Hsu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117717_bib76","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1016\/j.celrep.2019.11.018","article-title":"A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis","volume":"29","author":"Hoj","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117717_bib77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/OTT.S6909","article-title":"The dual kinase complex FAK-Src as a promising therapeutic target in cancer","volume":"3","author":"Bol\u00f3s","year":"2010","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.celrep.2026.117717_bib78","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/leu.2010.268","article-title":"ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1","volume":"25","author":"Thai","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.celrep.2026.117717_bib79","doi-asserted-by":"crossref","DOI":"10.4161\/cib.25421","article-title":"RIN1 regulates cell migration through RAB5 GTPases and ABL tyrosine kinases","volume":"6","author":"Balaji","year":"2013","journal-title":"Commun. Integr. Biol."},{"key":"10.1016\/j.celrep.2026.117717_bib80","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cub.2005.03.049","article-title":"RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration","volume":"15","author":"Hu","year":"2005","journal-title":"Curr. Biol."},{"key":"10.1016\/j.celrep.2026.117717_bib81","doi-asserted-by":"crossref","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","article-title":"GSEApy: a comprehensive package for performing gene set enrichment analysis in Python","volume":"39","author":"Fang","year":"2023","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2026.117717_bib82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol."},{"key":"10.1016\/j.celrep.2026.117717_bib83","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726007953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726007953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:31:58Z","timestamp":1793050318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726007953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2211124726007953"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117717","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117717"}}